help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on September 15, 2005, doi:10.1164/rccm.200409-1215OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200409-1215OCv1
172/11/1416    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sloane, A. J.
Right arrow Articles by Harry, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sloane, A. J.
Right arrow Articles by Harry, J. L.
American Journal of Respiratory and Critical Care Medicine Vol 172. pp. 1416-1426, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200409-1215OC


Original Article

Proteomic Analysis of Sputum from Adults and Children with Cystic Fibrosis and from Control Subjects

Andrew J. Sloane, Robyn A. Lindner, Sindhu S. Prasad, Lucille T. Sebastian, Susanne K. Pedersen, Michael Robinson, Peter T. Bye, Dennis W. Nielson and Jenny L. Harry

Proteome Systems, Ltd; Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia; and Department of Pediatrics, University of California, San Francisco, San Francisco, California

Correspondence and requests for reprints should be addressed to Andrew Sloane, Ph.D., Proteome Systems Ltd, Unit 1, 35-41 Waterloo Road, North Ryde, Sydney, NSW 2113, Australia. E-mail: andrew.sloane{at}proteomesystems.com

Rationale: Recurrent pulmonary exacerbations are associated with progressive lung disease in cystic fibrosis (CF). Current definitions of an exacerbation, although not precisely defined, include new/worsening symptoms, declining lung function, and/or changing radiologic appearance. Early diagnosis of exacerbations by rapid noninvasive means should expedite therapeutic intervention, thereby minimizing lung damage.

Objectives: To identify biomarkers of lung exacerbation for point-of-care monitoring of CF lung disease progression.

Methods: Saline-induced sputum was collected from adults with CF with an exacerbation and requiring hospitalization (FEV1 < 60%), a subset of these adults at hospital discharge, children with stable CF and preserved lung function (FEV1 > 70%), and control subjects (FEV1 > 80%). Sputum was arrayed by two-dimensional electrophoresis and differentially expressed proteins were identified by proteomic analysis.

Measurements and Main Results: Sputum profiles from adults with CF with an exacerbation were characterized by extensive proteolytic degradation and influx of inflammation-related proteins, with some adults with CF approaching a "healthy" protein profile after hospitalization. Two children with CF showed profiles and biomarker expression resembling those of adults with an exacerbation. Levels of differentially expressed myeloperoxidase, cleaved {alpha}1-antitrypsin, IgG degradation, interleukin-8, and total protein concentration, together with their correlation to FEV1, were statistically significant. Statistical correlation analyses indicated that changes in myeloperoxidase expression and IgG degradation were the strongest predictors of FEV1.

Conclusions: We identified extensive protein degradation and differentially expressed proteins as biomarkers of inflammation relating to pulmonary exacerbations. Prediction of exacerbation onset and more precise evaluation of the extent of resolution with treatment could be achieved by including biomarkers in standard assessment.

Key Words: {alpha}1-antitrypsin • exacerbation • immunoglobulin • inflammation • myeloperoxidase




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
R. D. Gray, G. MacGregor, D. Noble, M. Imrie, M. Dewar, A. C. Boyd, J. A. Innes, D. J. Porteous, and A. P. Greening
Sputum Proteomics in Inflammatory and Suppurative Respiratory Diseases
Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 444 - 452.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Gaggar, P. L. Jackson, B. D. Noerager, P. J. O'Reilly, D. B. McQuaid, S. M. Rowe, J. P. Clancy, and J. E. Blalock
A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation
J. Immunol., April 15, 2008; 180(8): 5662 - 5669.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
B. L Schulz, A. J Sloane, L. J Robinson, S. S Prasad, R. A Lindner, M. Robinson, P. T Bye, D. W Nielson, J. L Harry, N. H Packer, et al.
Glycosylation of sputum mucins is altered in cystic fibrosis patients
Glycobiology, July 1, 2007; 17(7): 698 - 712.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. J. Accurso
Update in cystic fibrosis 2005.
Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 944 - 947.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society
  ATS Quiz on Sleep Study Tracings